Jessica Boklan

Prof. Jessica Boklan

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2021 in American Journal of Hematology
Verified
Journal Article
Closed access
PDF file
KSKristin A. Shimano
Kristin A. Shimano
ANAnupama Narla
Anupama Narla
MRMelissa J. Rose
Melissa J. Rose
NGNicholas J. Gloude
Nicholas J. Gloude
SASteven W. Allen
Steven W. Allen
JBJessica Boklan
Jessica Boklan

5 October 2017 in Clinical Epigenetics
Verified
Journal Article
Open access
PDF file
LGLia Gore
Lia Gore
TTTimothy J. Triche
Timothy J. Triche
JFJason E Farrar
Jason E Farrar
DWDaniel Wai
Daniel Wai
CLChristophe Legendre
Christophe Legendre
BSBodour Salhia
Bodour Salhia
Decitabine is a deoxycytidine nucleoside derivative inhibitor of DNA-methyltransferases, which has been studied extensively and is approved for myelodysplastic syndrome in adults but with less focus in children. Accordingly, we conducted a phase 1 multicenter, randomized, open-label study to evaluate decitabine pre-treatment before standard induction therapy in children with newly diagnosed AML to assess safety and tolerability and explore a number of biologic endpoints. Twenty-four patients were fully assessable for all study objectives per protocol (10 in Arm A = epigenetic priming induction, 14 in Arm B = standard induction). All patients experienced neutropenia and thrombocytopenia. The most common grade 3 and 4 non-hematologic adverse events observed were gastrointestinal toxicities and hypophosphatemia. Plasma decitabine PK were similar to previously reported adult data. Overall CR/CRi was similar for the two arms. MRD negativity at end-induction was 85% in Arm A versus 67% in Arm B patients. DNA methylation measured in peripheral blood over the course of treatment tracked with blast clearance and matched marrow aspirates at day 0 and day 21. Unlike end-induction marrow analyses, promoter methylation in blood identified an apparent reversal of response in the lone treatment failure, 1 week prior to the patient’s marrow aspirate confirming non-response. Decitabine-induced effects on end-induction (day 35–43 following initiation of treatment) marrows in Arm A were reflected by changes in DNA methylation in matched paired marrow diagnostic aspirates. This first-in-pediatrics trial demonstrates that decitabine prior to standard combination chemotherapy is feasible and well tolerated in children with newly diagnosed AML. Pre-treatment with decitabine may represent a newer therapeutic option for pediatric AML, especially as it appears to induce important epigenetic alterations. The novel biological correlates studied in this trial offer a clinically relevant window into disease progression and remission. Additional studies are needed to definitively assess whether decitabine can enhance durability responses in children with AML. NCT01177540

8 August 2012 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
AEAbeer Abd Elmoneim
Abeer Abd Elmoneim
LGLia Gore
Lia Gore
RRRebecca M. Ricklis
Rebecca M. Ricklis
JBJessica Boklan
Jessica Boklan
TCTodd M Cooper
Todd M Cooper
RARobert J. Arceci
Robert J. Arceci

19 May 2024 in Pediatric Blood & Cancer
Verified
Journal Article
Open access
KSKristin A. Shimano
Kristin A. Shimano
GSGhadir Sasa
Ghadir Sasa
LBLarisa Broglie
Larisa Broglie
NGNicholas J. Gloude
Nicholas J. Gloude
KMKasiani Myers
Kasiani Myers
JBJessica Boklan
Jessica Boklan
Severe aplastic anemia (SAA) is a rare potentially fatal hematologic disorder. Although overall outcomes with treatment are excellent, there are variations in management approach, including differences in treatment between adult and pediatric patients. Certain aspects of treatment are under active investigation in clinical trials. Because of the rarity of the disease, some pediatric hematologists may have relatively limited experience with the complex management of SAA. The following recommendations reflect an up‐to‐date evidence‐based approach to the treatment of children with relapsed or refractory SAA.

6 September 2025 in Cancers
Verified
Journal Article
Open access
PDF file
JBJessica Boklan
Jessica Boklan
ALAnne-Marie Langevin
Anne-Marie Langevin
KBKevin Bielamowicz
Kevin Bielamowicz
KNKathleen Neville
Kathleen Neville
TTTanya M Trippett
Tanya M Trippett
NLNorman James Lacayo
Norman James Lacayo
Background: Novel therapies are needed for children, adolescents, and young adults with relapse/refractory leukemia or solid tumors. The proteasome inhibitor carfilzomib has demonstrated pre-clinical activity against several pediatric malignancies when used alone or in combination. Therefore, a multicenter dose-escalation phase 1 study of carfilzomib administered in combination with cyclophosphamide and etoposide was conducted. Methods: Study eligibility included an age of 6 months to <30 years with relapsed/refractory leukemia (stratum A) or a relapsed/refractory non-CNS solid tumor (stratum B), Karnofsky/Lansky score ≥ 50, and adequate organ function. A 5-day regimen of cyclophosphamide 440 mg/m2/day, etoposide 100 mg/m2/day, and carfilzomib was administered every 28 days with growth factor support. The carfilzomib starting dose was 11 mg/m2/day, and dose escalation followed a rolling-six design, managed independently for each stratum. Dose-limiting toxicity (DLT) was assessed during the first cycle, and disease response was assessed after one cycle (stratum A) or two cycles (stratum B). Results: Thirty-eight patients were treated (14 in stratum A; 24 in stratum B). For stratum A, the maximum tolerated dose (MTD) for carfilzomib was 11 mg/m2/day. Three DLTs were observed: thrombocytopenia, pericarditis, and posterior reversible encephalopathy syndrome (PRES). Most patients received one cycle. For stratum B, an MTD was not reached. The highest dose level administered and recommended in phase 2 (RP2D) was 20 mg/m2/days 1–2 and 36 mg/m2/days 3–5 for cycle 1, then 36 mg/m2 for days 1–5 of all subsequent cycles. There was a single DLT of PRES. A dose expansion for additional toxicity data was conducted. Overall, twenty patients received ≥ 2 cycles (range, 2–14). Conclusions: A 5-day schedule of carfilzomib/cyclophosphamide/etoposide was well-tolerated in patients with solid tumors. Patients with sarcomas benefited most, warranting further evaluation.

11 August 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
JBJessica Boklan
Jessica Boklan
ALAnne-Marie Langevin
Anne-Marie Langevin
KBKevin Bielamowicz
Kevin Bielamowicz
KNKathleen Neville
Kathleen Neville
TTTanya M Trippett
Tanya M Trippett
NLNorman Lacayo
Norman Lacayo
Background: Novel therapies are needed for children, adolescents, and young adults with relapse/refractory leukemia or solid tumors. The proteasome inhibitor carfilzomib has demonstrated pre-clinical activity against several pediatric malignancies when used alone or in combination. Therefore, a multicenter dose-escalation phase 1 study of car-filzomib administered in combination with cyclophosphamide and etoposide was con-ducted. Methods: Study eligibility included age 6 months to < 30 years with re-lapsed/refractory leukemia (stratum A) or relapsed/refractory non-CNS solid tumor (stratum B), Karnofsky/Lansky score ≥ 50, and adequate organ function. A 5-day regimen of cyclophosphamide 440 mg/m2/day, etoposide 100 mg/m2/day, and carfilzomib was administered every 28 days with growth factor support. The carfilzomib starting dose was 11 mg/m2/day and dose escalation followed a rolling-six design, managed inde-pendently for each stratum. Dose-limiting toxicity (DLT) was assessed during the first cycle and disease response was assessed after one cycle (stratum A) or two cycles (stra-tum B). Results: Thirty-eight patients were treated (14 in stratum A; 24 in stratum B). For stratum A, the maximum tolerated dose (MTD) for carfilzomib was 11 mg/m2/day. Three DLTs were observed: thrombocytopenia, pericarditis, and posterior reversible enceph-alopathy syndrome (PRES). Most patients received one cycle. For stratum B, an MTD was not reached. The highest dose level administered and recommended phase 2 dose was 20 mg/m2/days 1-2 and 36 mg/m2/days 3-5 for cycle 1, then 36 mg/m2 for days 1-5 of all subsequent cycles. There was a single DLT of PRES. A dose expansion for additional toxicity data was conducted. Overall, twenty patients received > 2 cycles (range, 2–14). Conclusions: A 5-day schedule of carfilzomib/cyclophosphamide/etoposide was well tolerated in patients with solid tumors. Patients with sarcomas benefited most, war-ranting further evaluation.